论文部分内容阅读
目的探讨瑞舒伐他汀对冠心病患者左心室重构的影响。方法将2010年2月-2011年6月入潍坊市益都中心医院治疗的70例左心室射血分数≤40%的冠心病患者,随机分成治疗组和对照组,两组均采用常规治疗:硝酸酯类强心甙、利尿剂及血管紧张素转换酶抑制剂(ACEI)、β-受体阻滞剂,治疗组在常规治疗基础上加用瑞舒伐他汀10mg/d,6个月后,观察心率、血压、心功能等相关指数的变化。结果对照组和治疗组治疗后心电图疗效比较,治疗组的显效率和总有效率显著高于对照组(P<0.05);治疗组较对照组心率和血压显著降低(P<0.05);治疗组左心室的射血分数、治疗组左心室舒张末容量指数、左心室收缩末容量指数、左室重量指数明显改善(P<0.05),而对照组变化不明显。结论瑞舒伐他汀能显著改善冠心病,改善左心室重构,改善心功能。
Objective To investigate the effect of rosuvastatin on left ventricular remodeling in patients with coronary heart disease. Methods From February 2010 to June 2011, 70 cases of coronary heart disease with left ventricular ejection fraction ≤ 40% were treated in Weidu Central Hospital of Weifang, and were randomly divided into treatment group and control group. Both groups were treated by routine treatment: Nitroglycerin cardiac glycosides, diuretics and angiotensin-converting enzyme inhibitors (ACEI), β-blockers, the treatment group on the basis of conventional therapy with rosuvastatin 10mg / d, 6 months later , Observed heart rate, blood pressure, cardiac function and other related index changes. Results Compared with the control group, the effective rate and the total effective rate of the treatment group were significantly higher than those of the control group (P <0.05). The heart rate and blood pressure of the treatment group were significantly lower than those of the control group (P <0.05) Left ventricular ejection fraction, left ventricular end-diastolic volume index, left ventricular end-systolic volume index, left ventricular mass index were significantly improved (P <0.05), while the control group did not change significantly. Conclusion Rosuvastatin can significantly improve coronary heart disease, improve left ventricular remodeling and improve cardiac function.